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We previously demonstrated that 𝗼-mangostin, 𝗾-mangostin, and 8-deoxygartanin have significant cytotoxic effects on human
melanomaSK-MEL-28cellline.Thecurrentstudyrevealedtheunderlyingmechanisms.𝗼-Mangostin(7.5𝜇g/mL)activatedcaspase
activity, with a 3-fold and 4-fold increased caspase 8 and 9 activity, respectively. The molecular mechanisms were investigated by
qRT-PCR for mRNA related to cell cycle arrest in G1 phase (p21
WAF1 and cyclin D1), apoptosis (cytochrome C, Bcl-2, and Bax),
and survival pathways (Akt1, NF𝜅B, and I𝜅B𝗼). 𝗼-Mangostin significantly upregulated mRNA expression of cytochrome C and
p21
WAF1 anddownregulatedthatofcyclinD1,Akt1,andNF𝜅B. 𝗾-MangostinsignificantlydownregulatedmRNAexpressionofAkt1
and NF𝜅B and upregulated p21
WAF1 and I𝜅B𝗼. 8-Deoxygartanin significantly upregulated the mRNA expression of p21
WAF1 and
downregulated that of cyclin D1 and NF𝜅B. The three xanthones significantly inhibited the mRNA expression of the BRAF V600E
mutation. Moreover, 𝗼-mangostin and 𝗾-mangostinsignificantlydownregulatedAktphosphorylationatSer473.Inconclusion,the
three xanthones induced an inhibitory effect on SK-MEL-28 cells by modulating the molecular targets involved in the apoptotic
pathways.
1. Introduction
Melanoma, the most fatal form of skin cancer, has been
increasing in incidence steadily worldwide for decades,
especially in populations of fair-skinned Caucasians [1, 2].
Although early stage melanoma is effectively removed by
surgery, later stages of this disease are difficult to treat and
have a low survival rate. Chemotherapies (e.g., Dacarbazine)
are used to treat advanced melanoma. However, their thera-
peutic efficacy is limited due to chemoresistance and toxicity
issues [3]. Therefore, new agents with a higher therapeutic
efficacy are needed for human melanoma.
Xanthones, a group of naturally occurring phenolic
compounds,areplentifulinthepericarpofmangosteen(Gar-
cinia mangostana Linn.) [4] and are also found in other
plants [5]. Anticancer activity is an important biological
activity of xanthones. Some xanthones have been shown to
inhibit the proliferation of a range of human cancer cells, as
described previously [6–8]. Also, 𝗼-mangostin, a major xan-
thone compound, can inhibit the metastasis of some types of
cancer cells in vitro and in vivo [7]. Our group demonstrated
the potent cytotoxicity of three xanthones (𝗼-mangostin, 𝗾-
mangostin, and 8-deoxygartanin) isolated from mangosteen
pericarp against human melanoma SK-MEL-28 cells [9].
Among these, 𝗼-mangostin showed the strongest activity.
We demonstrated that the effect of the three xanthones was
associated with cell cycle arrest in G1 and induction of apop-
tosis via caspase 3 activation and mitochondrial membrane
disruption. However, the molecular mechanism by which
thesexanthonesexertgrowthregulatoryandapoptoticeffects
was not known. Therefore, the current study determined
the underlying mechanisms of xanthone-induced cell cycle
arrest and apoptosis by investigating the expression of genes
potentially involved.2 BioMed Research International
In many cancers, activation of antiapoptotic factors can
lead to chemoresistance, as can reinforcement of survival
pathways. In melanoma, the PI3K/Akt (Akt) signalling path-
wayisconstitutivelyactivatedthroughmultiplemechanisms.
Activated Akt can phosphorylate many downstream targets
(e.g., Bad, Bax, and caspase-9) and suppress proapoptotic
transcription factors (e.g., FoxO and p53) [10–13]. Con-
sequently, activation of this signalling pathway can block
apoptosis, and thus supporting cancer cell growth [14, 15].
Also, activation of NF𝜅B has been observed in melanoma
[16] and has been associated with resistance to radiotherapy
andchemotherapy[17–19].Xanthonesmayinhibitmelanoma
cell proliferation via regulation of these signalling pathways.
Therefore, the current study examined the effect of down-
regulation of gene transcription in the survival pathways of
Akt1 and NF𝜅B, in addition to a number of genes related to
apoptosis and cell cycle progression.
2. Materials and Methods
2.1. Materials. 𝗼-Mangostin and 8-deoxygartanin were from
Phenomenex Australia Pty Ltd. (NSW, Australia) and 𝗾-
mangostin was from Biopurity Phytochemicals (Chengdu,
China)atgreaterthan98%purity.Trypsin-EDTAandtrypan
blue staining were from Sigma-Aldrich (St. Louis, USA).
Chemicals and xanthone preparation were as described in
Wang et al. [9].
2.2. Cell Culture and Cell Treatment. Human melanoma
SK-MEL-28 cell line was from the American Type Culture
Collection (ATCC HTB-72). Cells were cultured in DMEM
(Sigma, USA) supplemented with 10% heat-inactivated fetal
bovine serum (FBS; Invitrogen Corporation, Australia),
100U/mL penicillin, and 0.1mg/mL streptomycin (Thermo
Scientific, Melbourne, Australia). Cells were maintained in
an incubator with 5% CO2 at 37
∘C. Cells were free of
mycoplasma contamination as detected by PCR (data not
shown). Cell treatment was for 48h as described in Wang
et al. [9].
2.3.Caspase-8and9Assay. Caspaseactivitywasmeasuredby
using Caspase-Glo 8 and 9 assay kits according to the manu-
facturer’s instructions (Promega Corporation, Australia) [8].
2.4. Apoptosis Assay. T oc o n fi r mt h er o l eo fc a s p a s ei nt h e
apoptosis induced by these xanthones, pan-caspase inhibitor
(Z-VAD-FMK) (Promega Corporation, Australia) was used.
The inhibitor (60𝜇M) was added 2h before the addition of
the xanthone. The apoptosis induced by xanthone alone or
xanthone with caspase inhibitor (CI) was determined using
Annexin V-FITC and PI staining detected by flow cytometry
as previously described [9].
2.5. Cytochrome C Release Measurement. The release of cyto-
chrome C from the mitochondrial membrane was detected
using the InnoCyte Flow Cytometric Cytochrome C Release
Kit according to the manufacturer’s instructions (Merck,
Australia). Briefly, SK-MEL-28 cells were harvested after
48h treatment with the tested xanthones. 10
6 cells were
resuspended in 300𝜇L Permeabilization Buffer and incu-
b a t e df o r1 0 m i no ni c e .Th e nt h ec e l l sw e r efi x e dw i t h
4% paraformaldehyde and incubated for 20min at room
temperature, followed by being washed for three times using
1× washing buffer. The cells were incubated with blocking
buffer for 1h at room temperature. After that, the cells
were incubated with anticytochrome C mouse monoclonal
a n t i b o d y ,f o l l o w e db ys e c o n d a r ya n t i b o d yc o n j u g a t e dt o
FITC. Finally, the cells were resuspended in 500𝜇Lo fw a s h -
ing buffer and analysed by FACS Calibur Flow Cytometer
(Becton Dickinson, San Jose, CA, USA).
2.6. qRT-PCR. Real time reverse transcription-PCR (qRT-
PCR)wasperformedasdescribedpreviously[8]todetermine
mRNAlevelsofanumberofcellcycle-relatedgenes(p21
WAF1
and cyclin D1), apoptosis-related genes (Bcl-2, Bax, and
cytochrome C), and prosurvival-related genes (Akt, NF𝜅B,
I𝜅B𝗼, and BRAF V600E) on the SK-MEL-28 cells following
the 48h treatments. The details of primer sequences are
containedinWangetal.[8]withtheadditionofBRAFV600E
primer set (F: AGGTGATTTTGGTCTAGCTACAGA; R:
TAGTAACTCAGCAGCATCTCAGGGC; Accession num-
ber: HM459603.1; Product size: 149bp).
2.7. Western Blotting Analysis. Protein was isolated using
TRIzolsolution(Invitrogen,Australia)accordingtotheman-
ufacturer’s instructions. Protein concentration was deter-
mined using an EZQ protein quantitation kit (Molecular
Probes) using bovine serum albumin as the standard. The
total of 20𝜇go feac hsa m p lewasmix edwi thsodi umdodecyl
sulphate (SDS) sample buffer (50mM Tris-HCl pH 6.8, 4%
(v/v) glycerol, 0.8% (w/v) SDS, and 40mM DTT) and sub-
jected to SDS-PAGE using Criterion TGX Stain-Free precast
gel (Bio-Rad) as described previously [20]. Total protein was
imaged before and after transfer using a ChemiDoc MP
imager (Bio-Rad). Proteins were transferred to Immun-Blot
LF polyvinylidene difluoride (PVDF) membrane (0.45𝜇m;
Bio-Rad) using a Turbo Blot transfer unit (Bio-Rad). The
membrane was then blocked with 5% (w/v) nonfat dry skim
milk in TBS-T (20mM Tris base, 150mM NaCl, 0.1% (v/v)
Tween-20, pH 7.4) for 1h at room temperature, followed
by overnight incubation with primary antibody at 4
∘Co na
shaker. Nonbinding primary antibodies were removed by 2 ×
5minand2× 1 0m i nw a s h e si nT B S - Tp r i o rt oi n c u b a t i o n
with secondary antibodies (1:5000 dilution) for 1h at room
temperature. The membrane was then washed (2 × 5min
and 2 × 1 0m i nw a s h e si nT B S - T )a n dp l a c e di ne q u a lp a r t s
of stable peroxide buffer and luminol/enhancer solutions of
SuperSignalWestPicoChemiluminescentSubstrate(Thermo
Scientific, Illinois, USA) for 5min. Enhanced chemilumi-
nescence was detected using a LAS-4000 imager (FujiFilm
Global, Tokyo, Japan). All images were analysed using Image
J software to estimate the optical densities for each protein
band. To account for differences in loading, the net intensity
of the band of interest from each sample was normalised
to the net intensity of total protein within the same lane.
Changes in abundance of the protein of interest due toBioMed Research International 3
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Figure1:Caspase8(a)and9(b)activitiesweredeterminedusingluminescentkitsasdescribedinthemethodforSK-MEL-28celllinetreated
with xanthones for 48h. The values are shown as the mean ± SEM (𝑛=3 ). Treatments significantly different from the untreated control at
𝑃 < 0.05 are presented as ∗ and at 𝑃 < 0.01 as ∗∗.
treatment were compared by normalising to the untreated
cells control.
2.8. Statistical Analysis. All experiments were repeated at
least three times independently. Means and standard error of
mean (SEM) were calculated using Microsoft Excel 2007. The
statistical significance of the results was analysed using one-
way ANOVA followed by Tukey’s HSD post hoc test (equal
variances) or Dunnett’s T3 post hoc test (unequal variances).
TheanalysiswascarriedoutusingSPSSsoftware(version18).
𝑃 < 0.05 was considered statistically significant and 𝑃 < 0.01
as highly significant.
3. Results
3.1. 𝗼-Mangostin Increased Caspase 8 and 9 Activity of SK-
MEL-28 Cells. A significant increase in caspase 8 after 48h
treatment of SK-MEL-28 cells was observed only with 𝗼-
mangostin. Treatment with 𝗼-mangostin at 5𝜇g/mL resulted
in an approximately 1.6-fold increase (𝑃 < 0.05)a n da t
7.5 𝜇g/mL resulted in an approximately 3-fold increase (𝑃<
0.01) relative to untreated cells (Figure 1(a)).
Asignificantincreaseincaspase9wasalsoobservedafter
48h treatment with 𝗼-mangostin only. Treatment with 𝗼-
mangostin at 7.5𝜇g/mL resulted in an approximately 4-fold
increase (𝑃 < 0.05) relative to untreated cells (Figure 1(b)).
3.2. Apoptosis Induced by 𝗼-Mangostin in SK-MEL-28 Cells
Was Rescued by Pan-Caspase Inhibitor. The role of cas-
pase in the apoptosis induced by xanthones was confirmed
using pan-caspase inhibitor. As shown in Figure 2,t h e
𝗼-mangostin-induced apoptosis was reduced significantly
when the pan-caspase inhibitor was applied. The percentage
of apoptotic cells decreased to 11.7% in the presence of
the inhibitor from 36.4% in the absence of the inhibitor
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Figure2:ThetotalofapoptoticcellswasdeterminedusingAnnexin
V-FITC and PI staining after treatment with xanthone or with
combination of xanthone and caspase inhibitor (CI). The values are
shown as the mean ± SEM (𝑛=3 ). Significant difference in the
total apoptotic cells between xanthone alone and combination of
xanthone and CI is presented as ∗ (𝑃 < 0.05)a n d∗∗ (𝑃 < 0.01).
C stands for untreated control.
(Figure 2). However, no significant difference was observed
after treatment with 𝗾-mangostin and 8-deoxygartanin.
3.3. Xanthones Increased Cytochrome C Release from Mito-
chondria to Cytosol. Increases in cytochrome C release
from mitochondria to cytosol were observed for all treat-
ments. Treatment of SK-MEL-28 cells with 𝗼-mangostin, 𝗾-
mangostin, and 8-deoxygartanin significantly decreased %
mitochondrialcytochromeCto55.1%,55.8%,and74.1%com-
pared to the untreated cells (100%), respectively (Figure 3).4 BioMed Research International
3.4.XanthonesModulatedCellCycle-RelatedGeneExpression.
Our previous study demonstrated that treatment with xan-
thones induced significant increases in cell cycle arrest in G1
phase in SK-MEL-28 cells [9]. The current study examined
the effect of these xanthones on the modulation of the cell
cycle-related gene expression in SK-MEL-28 cells.
Significant increases in mRNA level of p21
WAF1 were
observed after treatment with the three tested com-
pounds (Figure 4(a)). The most marked effect was for
8-deoxygartanin, which induced an 87.1-fold increase of the
mRNA level of p21
WAF1 relative to the untreated control
(𝑃 < 0.01).
SignificantdecreasesinthemRNAlevelofcyclinD1were
observed after treatment with 𝗼-mangostin and 8-deoxy-
gartanin (Figure 4(b)). A 10-fold and 5-fold decrease of the
mRNA level of cyclin D1 relative to the untreated control was
induced by 𝗼-mangostin (𝑃 < 0.01)a n d8 - d e o x y g a r t a n i n
(𝑃 < 0.01), respectively.
3.5. Xanthones Modulated Apoptosis-Related Genes. To un-
d e r s t a n dt h em o l e c u l a rm e c h a n i s m so fa p o p t o s i si n d u c e d
by xanthones, we firstly examined the effect of xanthones
on the mRNA expression of cytochrome C, which is an
important signalling event in the intrinsic apoptotic acti-
vation pathway. The significant increases found after 48h
treatment with 𝗼-mangostin (7.5𝜇g/mL) and 𝗾-mangostin
(10𝜇g/mL) (Figure 5) were 8-fold and 12-fold, respectively.
We also examined the effect of xanthones on the mRNA
level of Bax and Bcl-2. However, no significant alterations in
the Bax and Bcl-2 were found after treatment with the tested
xanthones (data not shown).
3.6.XanthonesModulatedGenesinSurvivalPathways. Treat-
ment of SK-MEL-28 cells with 𝗼-mangostin (7.5𝜇g/mL) and
𝗾-mangostin (10𝜇g/mL) induced 3.8- and 3.2-fold decreases
of the mRNA level of Akt1, respectively (𝑃 < 0.05;
Figure 6(a)).
S i g n i fi c a n td e c r e a s e so ft h em R N Al e v e lo fN F 𝜅Bw e r e
found for SK-MEL-28 cells after treatment with 7.5𝜇g/mL of
𝗼-mangostin (3.7-fold), 10𝜇g/mL of 𝗾-mangostin (3.7-fold),
and 10𝜇g/mL of 8-deoxygartanin (1.7-fold) (Figure 6(b)).
However,asignificantincreaseofthemRNAlevelofI𝜅B𝗼
was found only after treatment with one concentration of 𝗾-
mangostin (10𝜇g / m L )w i t ha4 . 1 - f o l di n c r e a s er e l a t i v et ot h e
untreated control (𝑃 < 0.05; Figure 6(c)).
Significant decreases in the mRNA level from the BRAF
V600E mutant gene were observed after treatment with 𝗼-
mangostin,𝗾-mangostin,and8-deoxygartanin(Figure 6(d)).
The most marked effect was with 𝗾-mangostin, which
induced a 6.8-fold decrease of the mRNA level of BRAF
V 6 0 0 Er e l a t i v et ot h eu n t r e a t e dc o n t r o l( 𝑃 < 0.01).
3.7. Xanthones Modulated Protein Expression of Akt1 and
Phosphorylation at Ser473 and Thr308. 𝗼-Mangostin sig-
nificantly inhibited the protein expression of Akt1 and
phosphor-Akt (Ser473) in SK-MEL-28 cells (Figures 7(a) and
7(b)).𝗾-Mangostininhibitedtheexpressionofphosphor-Akt
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Figure 3: Mitochondrial cytochrome C was examined using flow
cytometryafter48htreatmentwith𝗼-mangostin,𝗾-mangostin,and
8-deoxygartanin. Data were obtained from 20,000 events and pre-
sented as the percentage of mitochondrial cytochrome C compared
to the untreated control. The values are shown as the mean ± SEM
ofthreeindependentexperiments.Treatmentssignificantlydifferent
from the untreated control at 𝑃 < 0.05 are presented as ∗ and
𝑃 < 0.01 as ∗∗.
(Ser473) (Figure 7(b)). No significant changes in phosphor-
Akt(Thr308)werefoundaftertreatmentwiththetestedthree
xanthones (Figure 7(c)).
4. Discussion and Conclusion
In the present study, we investigated the potential mech-
anisms underlying the antiproliferative effect of the three
xanthones on human melanoma SK-MEL-28 cells. Our
previous study demonstrated that treatment of SK-MEL-28
cells with xanthones induced G1 phase arrest [9]. The G1
phase of cell cycle is controlled by cyclin dependent kinases,
cyclin kinase inhibitors (CKI), and cyclins [21]. qRT-PCR
was used to measure the mRNA expression levels of genes
involved in cell cycle regulation. The genes studied were
cyclin D1 (involved at the G1/S boundary) and p21
WAF1 (a
universal CKI). The expression of p21
WAF1 was significantly
increased after treatment of SK-MEL-28 cells with the three
xanthone compounds. SK-MEL-28 cells possess mutant p53
[22], therefore the xanthone-induced increases in p21
WAF1
couldbep53independent.Additionally,significantdecreases
in the expression of cyclin D1 were observed after treatment
with 𝗼-mangostin and 8-deoxygartanin. Consistently, on
human prostate cancer 22Rv1 cells, 𝗼-mangostin has been
reported to induce cell cycle arrest in G1 phase by inhibition
of CDK4 via upregulating protein expression of p27
Kip1
and downregulating protein expression of cyclin D1 and
D3, phosphorylated retinoblastoma, and cyclin E [23]. The
mechanismofcellcyclearrestinducedbyxanthonescouldbe
studied further, for example, via the expression of additional
cyclins (e.g., A/E) and cyclin-dependent kinases (CDK) (e.g.,
CDK2/4/6).BioMed Research International 5
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Figure 4: Effect of xanthones on the mRNA expression of (a) p21
WAF1 and (b) cyclin D1 as determined by qRT-PCR for SK-MEL-28 cell
line treated with xanthones for 48h. The values are shown as the mean ± SEM (𝑛=4 ). Treatments significantly different from the untreated
control at 𝑃 < 0.05 are presented as ∗ and at 𝑃 < 0.01 as ∗∗.
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Apoptosisplays a criticalrolein thepreventionofcancer.
However, most cancer cells show resistance to cell death, and
melanoma cells are no exception. The resistance to apoptosis
could be required for tumour growth and likely contributes
to chemoresistance [20]. The resistance of melanoma to
apoptosismaybeduetoinactivationofproapoptoticeffectors
(e.g., loss of the p53 pathway) [24, 25] and activation of anti-
apoptotic factors (e.g., Bcl-2, Bcl-xL, and Mcl-1 are highly
expressedinmelanomacells)[26–28].Also,melanomashows
resistance to death receptor-mediated apoptosis (extrinsic
pathway), possibly due to resistance to CD95 stimulation
[29], and resistance to TNF-𝗼-mediated apoptosis [30]. We
previously demonstrated that the three tested xanthones,
especially 𝗼-mangostin, induced apoptosis on human SK-
MEL-28cell line[9]. The mechanisms of apoptosisare highly
complex, involving multiple molecular events. Generally,
there are two major apoptotic pathways: the intrinsic or
mitochondrial pathway and the extrinsic or death receptor
pathway[31,32].Caspases3and7areeffectorcaspaseswhich
are involved in both pathways. Caspases 8 and 9 are initiator
caspases which are involved in the extrinsic and the intrinsic
pathways, respectively [33, 34]. Both 𝗼-mangostin and 8-
deoxygartanin activated caspase 3/7 in human melanoma
SK-MEL-28 cells [9]. The current study demonstrated that
only 𝗼-mangostin induced significant activation of caspases
8 and 9 (Figures 1(a) and 1(b)). Consistently, 𝗼-mangostin
previously increased caspases 3, 8, and 9 activities in human
chondrosarcoma SW1353 cell line [35]. However, this is
not in agreement with findings of Matsumoto et al. [36]
w h or e p o r t e dt h a t𝗼-mangostin activated caspases 3 and
9, but not caspase 8. This apparent conflict in the data
may be because this compound exerts its activities via
different pathways in different types of cancer cells [7]. After
treatment with 8-deoxygartanin, caspase 9 activity was only
slightly increased, which was not significant. The results
indicated that 𝗼-mangostin could induce apoptosis through
both intrinsic and extrinsic pathways. Previously, the three
tested xanthones significantly decreased the mitochondrial
membrane potential of SK-MEL-28 cells [9], indicating that
𝗾-mangostin induced caspase-independent apoptosis via the
mitochondrial pathway. Caspase-independent apoptosis via
the mitochondrial pathway has also been reported after
treatment of colon cancer cells with 𝗼-mangostin [37]. In
thisstudy,activationofcaspaseswasconfirmedusingcaspase
inhibitors. Addition of the caspase inhibitor significantly
rescued the cell death induced by 𝗼-mangostin (Figure 2),
indicating that 𝗼-mangostin-induced apoptosis is mediated
through the activation of caspases.6 BioMed Research International
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Figure 6: Effect of xanthones on the mRNA expression of (a) Akt1, (b) NF𝜅B, (c) I𝜅B𝗼, and (d) BRAF V600E mutation as determined by
qRT-PCR for SK-MEL-28 cell line treated with xanthones for 48h. The values are shown as the mean ±SEM (𝑛=3 ).Treatmentssignificantly
different from the untreated control at 𝑃 < 0.05 are presented as ∗ and at 𝑃 < 0.01 as ∗∗.
To determine the molecular mechanism underlying the
apoptosis induced by xanthones, the genes involved in apop-
tosis were analyzed by qRT-PCR. Mitochondrial membrane
potentialdisruptionleadstothereleaseofcytochromeCinto
the cytoplasm. This will result in promotion of the formation
of the apoptosome and activation of caspase-9 (initiator
caspase) and consequent activation of downstream caspases
3 and 7 (executioner caspases) [38, 39]. We found that
treatment with 𝗼-mangostin and 𝗾-mangostin significantly
upregulated the mRNA expression of cytochrome C in SK-
MEL-28 cell line. Transcriptional activation of cytochrome
C can lead to increased protein expression in both the
cytosol and mitochondria [40]. The levels of cytochrome
C in the cytosol and mitochondria after treatment were
determined by flow cytometry. The results demonstrated
increases in cytochrome C release from mitochondria to
cytosol, suggesting the engagement of the mitochondria-
mediated apoptotic pathway.
The Bcl-2 family of proteins regulates the integrity of
the mitochondrial membrane and the efflux of proapoptotic
proteins from the mitochondria. There are three groups in
the Bcl-2 family: the first group is antiapoptotic (e.g., Bcl-
2 and Bcl-Xl), acting to preserve mitochondrial integrity
and prevent cells from apoptosis [41]; the second group
is proapoptotic (e.g., Bax and Bak), acting to disrupt the
mitochondrial membrane and promote cell apoptosis [42];
andthethirdgroupisalargefamily(e.g.,Bim,Bad,Bid,Noxa,
and Puma), interacting with other Bcl-2 family members
[43]. In this study, we examined the changes of mRNA
level in Bcl-2 (anti-apoptotic) and Bax (proapoptotic) after
treatment with xanthones. However, no significant changes
were found after treatment with the three xanthones. This
suggeststhatthesetwogenesarenotinvolvedintheapoptosis
induced by the three xanthones. This is consistent with
the studies of Matsumoto et al. [36]a n dW a n ge ta l .[ 8].
In contrast, Krajarng et al. [35]f o u n dt h a t𝗼-mangostin
increased Bax protein expression and decreased Bcl-2 in
human chondrosarcoma SW1353 cell line. Thus, the effect of
𝗼-mangostin appears to be cancer type dependent. It would
be interesting to monitor the protein levels of Bcl-2 and Bax
for the three xanthones to clarify the current result.
Akt plays an essential role in controlling cell survival,
growth, and apoptosis. It is constitutively activated in many
human cancers [44] by phospholipid binding and activation
loop phosphorylation at threonine 308 (Thr308) and by
phosphorylation within the carboxy terminus at serine 473BioMed Research International 7
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
R
e
l
a
t
i
v
e
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
o
f
 
t
o
t
a
l
 
A
k
t
1
5 0 7.5 5 10 5 10
Concentration (𝜇g/mL)
∗
(a)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
5 0 7.5 5 10 5 10
Concentration (𝜇g/mL)
R
e
l
a
t
i
v
e
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
o
f
p
h
o
s
p
h
o
r
-
A
k
t
 
(
S
e
r
4
7
3
)
∗
∗∗
(b)
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
R
e
l
a
t
i
v
e
 
p
r
o
t
e
i
n
 
e
x
p
r
e
s
s
i
o
n
 
o
f
p
h
o
s
p
h
o
r
-
A
k
t
 
(
Th
r
3
0
8
)
Untreated control
𝗼-Mangostin
𝗾-Mangostin
8-Deoxygartanin
5 0 7.5 5 10 5 10
Concentration (𝜇g/mL)
(c)
Figure7:EffectofxanthonesontheproteinexpressionofAkt1(a),phosphor-Akt(Ser473)(b),andphosphor-Akt(Thr308)(c)inSK-MEL-28
cell line was determined by western blot analysis. The values are shown as the mean ± SEM of three independent experiments. Treatments
significantly different from the untreated control at 𝑃 < 0.05 are presented as ∗ and at 𝑃 < 0.01 as ∗∗.
(Ser473) [45]. We demonstrated that treatment with 𝗼-
mangostin and 𝗾-mangostin significantly downregulated the
Akt1 mRNA expression (Figure 6(a)) and the Akt phospho-
rylation at Ser473 (Figure 7(b)). Downregulation at Thr308
was not observed. However, Shibata et al. [46]r e p o r t e d
that 𝗼-mangostin suppressed phospho-Akt-Thr308 but not
Ser473 in human mammary carcinoma MDA-MB231 cells.
Also, 𝗼-mangostin decreased the phosphorylation of Akt in
chondrosarcoma cells without affecting the total Akt protein
[35].Thisdifferencemightbeduetothecelltypeinvestigated.
Further study is required to clarify the different responses of
different cell types to xanthone compounds.
NF𝜅B is involved in regulation of cellular differentiation,
proliferation, and apoptosis. It contains five members with
p65 and p50 being the most abundant ones. All three tested
xanthonessignificantlydownregulatedthemRNAexpression
of NF𝜅B on the SK-MEL-28 cells. Consistently, 𝗼-mangostin
and 8-deoxygartanin inhibited p65 activation with IC50
values of 15.9 and 3.2𝜇M ,r e s p e c t i v e l y ,i na nE L I S AN F 𝜅B
assay [47]. I𝜅B𝗼 plays a key role in the NF𝜅Bp a t h w a y .
PhosphorylationofI𝜅B𝗼byIKKandsubsequentdegradation
is required for the activation of NF𝜅B[ 16]. In the current
study, a significant increase in the mRNA level of I𝜅B𝗼 was
found after treatmentwith 𝗾-mangostinonSK-MEL-28cells.
TheseresultssupportaroleforI𝜅B𝗼intheinhibitoryeffectof
NF𝜅Bi n d u c e db y𝗾-mangostin on SK-MEL-28 cells. ERK is
another important upstream regulator for NF𝜅B. Therefore,
the ERK pathway might be involved in downregulation of
NF𝜅B expression induced by the xanthones tested. Thus, the
mRNA and protein levels of these molecular targets warrants
further investigation.
BRAF gene mutations have been reported in most
malignant melanomas [48, 49]. BRAF V600E mutation
accounts for 89-90% of all the detected BRAF mutations.
BRAF V600E mutation leads to constitutive activation of
the MEK/ERK pathway, promoting cancer cell survival and
proliferation [50]. In the current study, significant downreg-
ulation of mRNA expression of BRAF V600E was observed
for human melanoma SK-MEL-28 cells treated with 𝗼-
mangostin,𝗾-mangostin,and8-deoxygartanin(Figure 6(d)).
RG7204 (PLX4032), a selective BRAF V600E inhibitor, has
potent inhibitory effects on the growth of melanoma harbor-
ing this mutation both in vitro and in vivo [51]. Particularly,
PLX4032 was reported to inhibit the growth of SK-MEL-
28 cells [52]. It is currently in phase II and phase III
clinical trials [51]. GSK2118436 is another successful example8 BioMed Research International
of treating melanoma by targeting BRAF mutations [53].
The current results indicate that xanthones have potential
as antimelanoma drugs via targeting of the BRAF V600E
mutation. Given the role of BRAF V600E in the MAPK
pathway, it is predicted that 𝗼-mangostin could inhibit the
activation of MEK/ERK. Consistently, 𝗼-mangostin has been
reported to downregulate MAPK pathway by inhibiting ERK
and JNK on human colon DLD-1 cells [54]a n dh um a nc h o n-
drosarcoma SW1353 cells [35]. To the best of our knowledge,
this study is the first demonstration of the inhibitory effect
of xanthonecompounds on BRAF V600E mutation.It would
be interesting to investigate the effect of xanthones on the
activation of MEK/ERK in SK-MEL-28 cells using western
blotting analysis in the future.
In the current study, the gene expression was tested
at 48h when significant apoptosis occurred. However, if
the target gene expression was only examined at this one
time point, the alteration of mRNA expression induced by
xanthone compounds may be underestimated. The changes
at transcriptional level occur earlier than those at protein
level. Before the apoptosis is manifest at the cellular level,
the mRNA expression level of target genes may reach a peak
a n dt h e nd e c r e a s e .I nt h ef u t u r e ,a d d i t i o n a lt i m ep o i n t se a r l y
in the process of apoptosis could be studied (e.g., 2, 4, 6,
12, and 24h) to detect the peak of mRNA expression of
the target genes. Additionally, the effect of xanthones could
be tested on a range of melanoma cell lines with different
genetic backgrounds to investigate the role of mutant genes
in influencing efficacy. Selectivity of xanthones should also
be tested using noncancerous melanocyte cells in the future.
Moreover,theothermoleculartargetsinthisstudyneedtobe
verified at the protein level by Western Blot analysis. In vivo
studies are required to determine the therapeutic efficacy of
xanthones.
In conclusion, our study indicates that the antiprolif-
erative and apoptotic effects of these three xanthones on
human melanoma SK-MEL-28 cell line are via modulation
o ft h eg e n e si n v o l v e di nt h ec e l lc y c l ea n da p o p t o s i sp a t h w a y ,
together with downregulation of the mRNA expression of
Akt1, NF𝜅B, and BRAF V600E. Understanding mechanisms
of xanthone action should allow for the design of combina-
tion treatment using xanthones with other therapies, based
on molecular targets.
Conflict of Interests
The authors declare that they have no conflict of interests.
Disclosure
Thestudysponsorsdidnothaveanyinvolvementinthestudy
design or in the collection, analysis, and interpretation of
data; in the writing of the manuscript, or in the decision to
submit the manuscript for publication.
Acknowledgments
Jing J. Wang gratefully acknowledges Flinders University for
awarding an EIPRS scholarship. The research was supported
by Klein Research Institute Ltd, Adelaide, Australia, and
Flinders University Underwriting Grant. The authors are
thankful to Dr. George Mayne from the Department of
Surgery, Flinders University, Adelaide, Australia, for his kind
help with qRT-PCR methods and analysis.
References
[1] S. Gupta and H. Mukhtar, “Chemoprevention of skin cancer
through natural agents,” Skin Pharmacology and Applied Skin
Physiology,v o l .1 4 ,n o .6 ,p p .3 7 3 – 3 8 5 ,2 0 0 1 .
[ 2 ]K .N o u r i ,E d . ,Skin Cancer, McGraw-Hill Medical, New York,
NY, USA, 2008.
[3] A. Orouji, S. Goerdt, and J. Utikal, “Systemic therapy of non-
resectablemetastaticmelanoma,”Cancers,vol.2,no .2,p p .955–
969, 2010.
[ 4 ]Y .A k a o ,Y .N a k a g a w a ,M .I i n u m a ,a n dY .N o z a w a ,“ A n t i -
cancer effects of xanthones from pericarps of mangosteen,”
InternationalJournalofMolecularSciences,vol.9 ,no .3,pp .355–
370, 2008.
[ 5 ]H .A .J u n g ,B .N .S u ,W .J .K e l l e r ,R .G .M e h t a ,a n dA .
D. Kinghorn, “Antioxidant xanthones from the pericarp of
Garcinia mangostana (Mangosteen),” Journal of Agricultural
and Food Chemistry,v o l .5 4 ,n o .6 ,p p .2 0 7 7 – 2 0 8 2 ,2 0 0 6 .
[6] J. Pedraza-Chaverri, N. C´ ardenas-Rodr´ ıguez, M. Orozco-
Ibarra, and J. M. P´ erez-Rojas, “Medicinal properties of man-
gosteen(Garciniamangostana),”FoodandChemicalToxicology,
vol. 46, no. 10, pp. 3227–3239, 2008.
[ 7 ]T .S h a n ,Q .M a ,K .G u oe ta l . ,“ X a n t h o n e sf r o mm a n g o s t e e n
extractsasnaturalchemopreventiveagents:potentialanticancer
drugs,” Current Molecular Medicine, vol. 11, no. 8, pp. 666–677,
2011.
[ 8 ] J .J .W a n g ,Q .H .S h i ,W .Z h a n g ,a n dB .J .S a n d e r s o n ,“ A n t i - s k i n
cancer properties of phenolic-rich extract from the pericarp of
mangosteen (Garcinia mangostana Linn.),” Food and Chemical
Toxicology,v o l .5 0 ,n o .9 ,p p .3 0 0 4 – 3 0 1 3 ,2 0 1 2 .
[9] J. J. Wang, B. J. S. Sanderson, and W. Zhang, “Cytotoxic effect
of xanthones from pericarp of the tropical fruit mangosteen
(Garcinia mangostana Linn.) on human melanoma cells,” Food
and Chemical Toxicology, vol. 49, no. 9, pp. 2385–2391, 2011.
[10] S.R.Datta,H.Dudek,T.Xuetal.,“AktphosphorylationofBAD
couples survival signals to the cell-intrinsic death machinery,”
Cell,v o l .9 1 ,n o .2 ,p p .2 3 1 – 2 4 1 ,1 9 9 7 .
[11] M. H. Cardone, N. Roy, H. R. Stennicke et al., “Regulation of
cell death protease caspase-9 by phosphorylation,” Science,v o l .
282, no. 5392, pp. 1318–1321, 1998.
[ 1 2 ]S .J .G a r d a i ,D .A .H i l d e m a n ,S .K .F r a n k e le ta l . ,“ P h o s p h o r y -
lation of Bax ser184 by Akt regulates its activity and apoptosis
inneutrophils,”TheJournalofBiologicalChemistry,vol.279 ,no .
20, pp. 21085–21095, 2004.
[13] B.D.ManningandL.C.Cantley,“AKT/PKBsignaling:navigat-
ing downstream,” Cell,v o l .1 2 9 ,n o .7 ,p p .1 2 6 1 – 1 2 7 4 ,2 0 0 7 .
[14] J. B. Easton and P. J. Houghton, “mTOR and cancer therapy,”
Oncogene,v o l .2 5 ,n o .4 8 ,p p .6 4 3 6 – 6 4 4 6 ,2 0 0 6 .
[15] D. A. Guertin and D. M. Sabatini, “Defining the role of mTOR
in cancer,” Cancer Cell,v o l .1 2 ,n o .1 ,p p .9 – 2 2 ,2 0 0 7 .
[16] R. Ravi and A. Bedi, “NF-𝜅B in cancer—a friend turned foe,”
Drug Resistance Updates,v o l .7 ,n o .1 ,p p .5 3 – 6 7 ,2 0 0 4 .
[ 1 7 ] K .H .Se o ,H .M .K o ,H .A .K i me ta l . ,“ P l a t e l e t - a c t i v a t i n gf a c t o r
induces up-regulation of antiapoptotic factors in a melanomaBioMed Research International 9
celllinethroughnuclearfactor-𝜅Bactivation,”CancerResearch,
v o l .6 6 ,n o .9 ,p p .4 6 8 1 – 4 6 8 6 ,2 0 0 6 .
[ 1 8 ] A .M u n s h i ,J .F .K u r l a n d ,T .N i s h i k a w a ,P .J .C h i a o ,M .A n d r e e ff ,
and R. E. Meyn, “Inhibition of constitutively activated nuclear
factor-𝜅Bradiosensitizershumancells,”MolecularCancerTher-
apeutics,v o l .3 ,n o .8 ,p p .9 8 5 – 9 9 2 ,2 0 0 4 .
[19] M. F. Romano, R. Avellino, A. Petrella, R. Bisogni, S. Romano,
and S. Venuta, “Rapamycin inhibits doxorubicin-induced
NF-𝜅B/Rel nuclear activity and enhances the apoptosis of
melanoma cells,” European Journal of Cancer,v o l .40,n o .1 8,p p .
2829–2836, 2004.
[20] J. Eberle, B. M. Kurbanov, A. M. Hossini, U. Trefzer, and L. F.
Fecker, “Overcoming apoptosis deficiency of melanoma-Hope
for new therapeutic approaches,” Drug Resistance Updates,v o l .
10, no. 6, pp. 218–234, 2007.
[21] S. K. Mantena, S. D. Sharma, and S. K. Katiyar, “Berberine
inhibits growth, induces G1 arrest and apoptosis in human epi-
dermoid carcinoma A431 cells by regulating Cdki-Cdk-cyclin
cascade, disruption of mitochondrial membrane potential and
cleavage of caspase 3 and PARP,” Carcinogenesis,v o l .2 7 ,n o .1 0 ,
pp. 2018–2027, 2006.
[22] M.S.Soengas,P.Capodieci,D.Polskyetal.,“Inactivationofthe
apoptosis effector Apaf-1 in malignant melanoma,” Nature,v o l .
409, no. 6817, pp. 207–211, 2001.
[23] J. J. Johnson, S. M. Petiwala, D. N. Syed et al., “𝗼-mangostin,
a xanthone from mangosteen fruit, promotes cell cycle arrest
in prostate cancer and decreases xenograft tumor growth,”
Carcinogenesis,v o l .3 3 ,n o .2 ,p p .4 1 3 – 4 1 9 ,2 0 1 2 .
[24] M. M¨ uller, E. S. Schleithoff, W. Stremmel, G. Melino, P. H.
K r a m m e r ,a n dT .S c h i l l i n g ,“ O n e ,t w o ,t h r e e - p 5 3 ,p 6 3 ,p 7 3a n d
chemosensitivity,” Drug Resistance Updates,v o l .9 ,n o .6 ,p p .
288–306, 2006.
[25] Q. Yu, “Restoring p53-mediated apoptosis in cancer cells: new
opportunities for cancer therapy,” Drug Resistance Updates,v o l .
9 ,n o .1 - 2 ,p p .1 9 – 2 5 ,2 0 0 6 .
[26] E.Selzer,H.Schlagbauer-Wadl,I.Okamoto,H.Pehamberger,R.
P¨ otter, and B. Jansen, “Expression of Bcl-2 family members in
humanmelanocytes,inmelanomametastasesandinmelanoma
cell lines,” Melanoma Research, vol. 8, no. 3, pp. 197–203, 1998.
[ 2 7 ]A .M .H o s s i n i ,J .E b e r l e ,L .F .F e c k e r ,C .E .O r f a n o s ,a n dC .C .
Geilen, “Conditional expression of exogenous Bcl-XS triggers
apoptosis in human melanoma cells in vitro and delays growth
of melanoma xenografts,” FEBS Letters,v o l .5 5 3 ,n o .3 ,p p .2 5 0 –
256, 2003.
[28] K. G. Wolter, M. Verhaegen, Y. Fern´ andez et al., “Therapeutic
window for melanoma treatment provided by selective effects
of the proteasome on Bcl-2 proteins,” Cell Death and Differenti-
ation, vol. 14, no. 9, pp. 1605–1616, 2007.
[29] M. Raisova, M. Bektas, T. Wieder et al., “Resistance to
CD95/Fas-induced and ceramide-mediated apoptosis of
human melanoma cells is caused by a defective mitochondrial
c y t o c h r o m ecr e l e a s e , ”FEBS Letters,v o l .4 7 3 ,n o .1 ,p p .2 7 – 3 2 ,
2000.
[30] V. N. Ivanov, A. Bhoumik, and Z. Ronai, “Death receptors and
melanomaresistancetoapoptosis,”Oncogene,vol.22,no.20,pp.
3152–3161, 2003.
[31] S.FuldaandK.M.Debatin,“Extrinsicversusintrinsicapoptosis
pathways in anticancer chemotherapy,” Oncogene,v o l .2 5 ,n o .
34, pp. 4798–4811, 2006.
[32] S. Elmore, “Apoptosis: a review of programmed cell death,”
Toxicologic Pathology,v o l .3 5 ,n o .4 ,p p .4 9 5 – 5 1 6 ,2 0 0 7 .
[33] A. Ashkenazi and V. M. Dixit, “Death receptors: signaling and
modulation,” Science, vol. 281, no. 5381, pp. 1305–1308, 1998.
[34] D. R. Green and G. P. Amarante-Mendes, “The point of no
return: mitochondria, caspases, and the commitment to cell
death,” Results and Problems in Cell Differentiation,v o l .2 4 ,p p .
45–61, 1998.
[35] A. Krajarng, Y. Nakamura, S. Suksamrarn, and R. Watanapok-
asin, “𝗼-mangostin induces apoptosis in human chondrosar-
coma cells through downregulation of ERK/JNK and Akt
signaling pathway,” J o u r n a lo fA g r i c u l t u r a la n dF o o dC h e m i s t r y ,
vol. 59, no. 10, pp. 5746–5754, 2011.
[36] K. Matsumoto, Y. Akao, H. Yi et al., “Preferential target is
mitochondria in 𝗼-mangostin-induced apoptosis in human
leukemia HL60 cells,” Bioorganic and Medicinal Chemistry,v o l .
1 2 ,n o .2 2 ,p p .5 7 9 9 – 5 8 0 6 ,2 0 0 4 .
[37] K. Matsumoto, Y. Akao, K. Ohguchi et al., “Xanthones induce
cell-cycle arrest and apoptosis in human colon cancer DLD-1
cells,” Bioorganic and Medicinal Chemistry,v o l .1 3 ,n o .2 1 ,p p .
6064–6069, 2005.
[ 3 8 ] H .Z o u ,W .J .H e n z e l ,X .L i u ,A .L u t s c h g,a n dX .W a n g,“ A p a f - 1 ,
ahumanproteinhomologoustoC.elegansCED-4,participates
in cytochrome c-dependent activation of caspase-3,” Cell,v o l .
9 0 ,n o .3 ,p p .4 0 5 – 4 1 3 ,1 9 9 7 .
[39] J. Rodriguez and Y. Lazebnik, “Caspase-9 and APAF-1 form an
active holoenzyme,” Genes and Development,v o l .1 3 ,n o .2 4 ,p p .
3179–3184, 1999.
[40] D. Chandra, J. Liu, and D. G. Tang, “Early mitochondrial
activation and cytochrome c up-regulation during apoptosis,”
Th eJ o u r n a lo fB i o l o g i c a lC h e m i s t r y ,v o l .2 7 7 ,n o .5 2 ,p p .5 0 8 4 2 –
50854, 2002.
[41] J. M. Adams and S. Cory, “The Bcl-2 protein family: arbiters of
cell survival,” Science, vol. 281, no. 5381, pp. 1322–1326, 1998.
[42] B. Antonsson and J. C. Martinou, “The Bcl-2 protein family,”
Experimental Cell Research,v o l .2 5 6 ,n o .1 ,p p .5 0 – 5 7 ,2 0 0 0 .
[43] D. C. S. Huang and A. Strasser, “BH3-only proteins—essential
initiators of apoptotic cell death,” Cell,v o l .1 0 3 ,n o .6 ,p p .8 3 9 –
842, 2000.
[44] J. R. Testa and A. Bellacosa, “AKT plays a central role in
tumorigenesis,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 98, no. 20, pp. 10983–10985,
2001.
[ 4 5 ] D .R .A l e s s i ,M .A n d j e l k o v i c ,B .C a u d w e l le ta l . ,“ M e c h a n i s mo f
activation of protein kinase B by insulin and IGF-1,” The EMBO
Journal,v o l .1 5 ,n o .2 3 ,p p .6 5 4 1 – 6 5 5 1 ,1 9 9 6 .
[46] M. A. Shibata, M. Iinuma, J. Morimoto et al., “𝗼-mangostin
extracted from the pericarp of the mangosteen (Garcinia man-
gostana Linn) reduces tumor growth and lymph node metas-
tasis in an immunocompetent xenograft model of metastatic
mammarycancer carryingap53mutation,”BMCMedicine,vol.
9, article 69, 2011.
[47] A. R. Han, J. A. Kim, D. D. Lantvit et al., “Cytotoxic xanthone
constituentsofthestembarkofGarciniamangostana(mangos-
teen),”JournalofNaturalProducts,vol.72,no.11,pp.2028–2031,
2009.
[ 4 8 ]A .G o r d e n ,I .O s m a n ,W .G a ie ta l . ,“ A n a l y s i so fB R A Fa n d
N-RAS mutations in metastatic melanoma tissues,” Cancer
Research, vol. 63, no. 14, pp. 3955–3957, 2003.
[49] H. Davies, G. R. Bignell, C. Cox et al., “Mutations of the BRAF
gene in human cancer,” Nature,v o l .4 1 7 ,n o .6 8 9 2 ,p p .9 4 9 – 9 5 4 ,
2002.10 BioMed Research International
[50] R. Kumar, S. Angelini, K. Czene et al., “BRAF mutations in
metastatic melanoma: a possible association with clinical out-
come,” Clinical Cancer Research,v o l .9 ,n o .9 ,p p .3 3 6 2 – 3 3 6 8 ,
2003.
[51] H. Yang, B. Higgins, K. Kolinsky et al., “RG7204 (PLX4032),
a selective BRAFV600E inhibitor, displays potent antitumor
activity in preclinical melanoma models,” Cancer Research,v o l .
7 0 ,n o .1 3 ,p p .5 5 1 8 – 5 5 2 7 ,2 0 1 0 .
[ 5 2 ]E .W .J o s e p h ,C .A .P r a t i l a s ,P .I .P o u l i k a k o se ta l . ,“ Th e
RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell
proliferation in a V600E BRAF-selective manner,” Proceedings
of the National Academy of Sciences of the United States of
America,v o l .1 0 7 ,n o .3 3 ,p p .1 4 9 0 3 – 1 4 9 0 8 ,2 0 1 0 .
[53] D .S.Hong,L.V ence,G.Falchooketal.,“BRAF(V600)inhibitor
GSK2118436 targeted inhibition of mutant BRAF in cancer
patients does not impair overall immune competency,” Clinical
Cancer Research,v o l .1 8 ,n o .8 ,p p .2 3 2 6 – 2 3 3 5 ,2 0 1 2 .
[54] Y. Nakagawa, M. Iinuma, T. Naoe, Y. Nozawa, and Y. Akao,
“Characterized mechanism of 𝗼-mangostin-induced cell death:
caspase-independent apoptosis with release of endonuclease-
G from mitochondria and increased miR-143 expression in
humancolorectalcancerDLD-1cells, ”BioorganicandMedicinal
Chemistry,v o l .1 5 ,n o .1 6 ,p p .5 6 2 0 – 5 6 2 8 ,2 0 0 7 .Submit your manuscripts at
http://www.hindawi.com
Pain
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
The Scientific 
World Journal
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com
Volume 2014
Toxins
Journal of
Vaccines
Journal of
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Antibiotics
International Journal of
Toxicology
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Stroke
Research and Treatment
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Drug Delivery
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Advances in 
Pharmacological 
Sciences
Tropical Medicine
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Medicinal Chemistry
International Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Addiction
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
BioMed 
Research International
Emergency Medicine 
International
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
  Autoimmune 
Diseases
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
 Anesthesiology 
Research and Practice
Scientifica
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Journal of
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
Pharmaceutics
Hindawi Publishing Corporation
http://www.hindawi.com Volume 2014
MEDIATORS
INFLAMMATION
of